Bubbles, Google and Schemes…Oh My!
This week’s BioBlog explores articles that span several industries. We look at Technology, Pharmaceuticals, Government, and Education as they all work to improve, advocate and reveal what happens behind the scenes in the war on cancer.
In this piece from the online magazine, Fierce Healthcare, Bryan Rotella, founder and managing shareholder of Rotella Legal Group, cites a conversation with health insurance expert Joe Cortelli, who noted that “we have done nothing to improve the outcomes of the 10 percent of the population that drives 80 percent of our claims costs.”
Stanford’s forthcoming Clinical Genomics Service, which puts genomic sequencing into the hands of clinicians to help diagnose disease, will be built using Google Genomics
This article from Bloomberg states, “Celgene, which reported $9.3 billion in revenue last year, is the latest pharmaceutical titan to come under fire in connection with patient-assistance charities, which set up dozens of funds to provide co-pay assistance to people with specific diseases”.
This article from AJMC.com states that come 2017, nilotinib (Tasigna), imatinib (Gleevec), enzalutamide (Xtandi), and filgrastim (Neupogen) will no longer be on the preferred drug list for CVS—they will be replaced by lower cost generic versions or biosimilars.
The National Institutes of Health has announced plans to dole out $55 million in grants over five years to enlist 1 million volunteers to allow access to their clinical data from electronic health records, use mobile health devices and apps to track activity in real time.
Dr. Christopher Sweeney, an oncologist at Boston’s Dana-Farber Cancer Institute, and author of the study, states, “Our findings support the belief that early diagnosis and management is key, and removal of barriers to access to health care should be implemented.”